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Abstract 
Osteoarthritis (OA) is characterized by degradation of joint cartilage which produces severe pain and swelling leading to immobility 
of the joint. OA can affect people of all age, gender and geographical locations, and the cost associated with long term medication, 
hospitalization and the loss of daily work hours stigmatizes the patient’s life. Conventionally, the treatment of OA is done with 
analgesic to relieve pain, but due to notorious side effects profile of NSAIDs and corticosteroids, dependence phenomenon with 
opioids and continuous underlying degradation of joint, the analgesics cannot be relied upon as sole therapeutic agent. Physical 
therapies, exercise, modification of lifestyle and use of supportive devices have shown effectiveness in prevention and treatment of 
mild OA. With the application of multidisciplinary approaches in medical research, many pharmacological and non-pharmacological 
interventions have evolved with optimistic claims of relieving joint pain and swelling. More recently, disease modifying OA drugs 
(DMOADs) have shown promising results in preventing cartilage degradation and induction of cartilage regeneration in experimental 
models as well as initial phases of clinical trials. The diversity of individual needs and complex comorbidities calls for patient 
oriented treatment plan, a goal which can be achieved effectively by multidisciplinary health care team. This review will provide an 
in-depth review of all clinically accepted conventional and nonconventional interventions for symptomatic relief of pain as well as 
novel disease modifying pharmacological and non-pharmacological modalities. 
Keywords: Diacerein, DMOADs, Glucosamine, Osteoarthritis, Prevalence in Pakistan. 
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INTRODUCTION 
Osteoarthritis (OA) is a chronic disease of joints 
characterized by degeneration and progressive loss of 
articular cartilage. Bone degradation in OA is followed by 
bone remodeling. This degeneration and remodeling cycles 
may lead to permanent deformity of the joints. OA affect 
people of all ages however it is more common in old age 
groups of all races. OA may be initiated by multiple factors 
including genetic, developmental, traumatic and metabolic 
factors (Ellis et al., 2011).  
OA is primarily a disease of cartilage. It usually affects 
specific joints including knee, hip, hands (fingers and thumb) 
and spine (neck and lower back). In osteoarthritis, the 
surface layer of cartilage breaks and wears away. This 
allows bones under the cartilage to rub together, causing 
pain, swelling and loss of motion of the joint (Shari and Joan, 
2015). OA should be differentiated from rheumatoid arthritis 
(RA) which is an autoimmune disease. RA also involves 
autoimmune reactions against skin, liver and eyes etc. which 
are not affected in OA. Additionally, OA mostly involves only 
one joint while RA is symmetrical, that is, if one joint is 
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affected, the same joint on the opposite side of the body is 
also affected. 
Arthritis is the most common cause of physical disability 
and has big economic impact on patient life. Osteoarthritis is 
the most prevalent of arthritic diseases, almost 15 times 
more prevalent than rheumatoid arthritis (Myasoedova et al., 
2010). In USA, about 7.9% young adults report OA, 29.8% 
persons of the age of 45-65 years are diagnosed with OA 
while another study found that almost every person above 
75 years has at least one joint involved. In osteoarthritic 
adults, 66% doctors reported cases are obese (Cheng et al., 
2010; Margaret et al., 2002). In Pakistan a large number of 
persons report OA. In 2005, 30% Pakistani males and 47% 
Pakistani females self-reported OA (Shaikh and Shaikh, 
2005). Rheumatoid arthritis is a disease of modern 
civilization attacking people in every part of the world. Ashraf 
et al. (2016) reported that the prevalence of rheumatoid 
arthritis was more in males (55%) compared to females 
(45%) in Narowal, Pakistan. Akhter et al. (2011) compared 
Pakistani and Indian arthritic population to European and 
North American arthritic population and found that the 
prevalence of OA is higher in developed countries as 
compared to developing countries including India and 
Pakistan. They also observed clear difference in the 
presentation patterns of the disease, especially in younger 
age groups. 
OA management includes changes in lifestyle, 
pharmacological interventions as well as innovative 
supportive devices. Allopathic, ayurvedic and nutritional 
supplements are pharmacological options which are widely 
used for OA management. Many classes of pharmacological 
agents have been reported to treat OA including pain 
relieving analgesics and disease modifying OA drugs 
(DMOAD). However the claim of these treatment options 
ranges from sub-optimistic to highly pessimistic. This review 
highlights epidemiology and etiology of OA, and the 
advances in treatment options including discovery of novel 
targets for therapeutic applications and their effectiveness in 
clinical set ups.  
                                                      
ETIOLOGY 
To understand the etiology of OA, it is first desirable to 
understand the structure of the joint (Figure 1). A joint 
consists of cartilage, joint capsule, synovium, synovial fluid 
and surrounding tissues of ligaments, tendons and muscles. 
Cartilage is a hard but slippery tissue that covers the ends of 
bones where they meet to form a joint. Healthy cartilage 
allows bones to glide over one another during physical 
movement. Joint capsule is a membrane sac that encloses 
joint bones and it surrounding tissues. Synovium is a 
membrane inside joint that secretes synovial fluid, the fluid 
that lubricates the joints. Tissues, ligaments and tendons 
help joint to bend and move. Ligaments and tendons are 
tough and cord-like tissues that connect bones with bones 
and tissues, respectively. The elasticity and compressibility 
in cartilage is imparted by extracellular matrix which consists 
of chondrocytes (1-2%), liquid phase (70-80%) and solid 
phase consisting of collagens and proteoglycans. Ligaments 
connect one bone to another while tendons connect a 
muscle with a bone (Ellis et al., 2011). 
Nature has kept an intelligent balance of remodeling 
process in which low levels of catabolic and anabolic 
enzymes work side by side. OA arises when this balance is 
shifted to catabolic side i.e. cartilage breakdown rate 
exceeds the cartilage synthesis rate. This degradation in OA 
is caused by matrix metalloproteinases (MMPs) which can 
degrade collagen and proteoglycans of joints. These 
enzymes are secreted as pro-enzymes by synovium 
membrane and chondrocytes, and require enzymatic 
cleavage for activation. Normally, activity of these enzymes 
is controlled by tissue inhibitors of MMPs (TIMPs) (Muroski 
et al., 2008). Synthesis of MMPs can be induced by pro-
inflammatory interleukin-1 (IL-1) and to some extent by 
tumor necrosis factor alpha (TNF-alpha). IL-1 degrades 
cartilage in two ways i.e. by inducing catalytic pathways and 
by suppressing remodeling pathways (Shari and Joan, 
2015).  
Induction of Cartilage Catalysis: In normal 
circumstances, the action of IL-1 is antagonized by the IL-1 
receptor antagonist (IL-1RA). But in arthritis, excessive 
synthesis of IL-1 or reduction in IL-1RA level leads to 
excessive synthesis of MMPs that outweigh the synthesis of 
inhibitory TIMPs. This imbalance in the favor of MMPs over-
production produces cartilage degradation. IL-1 is also 
associated with production of nitric oxide (NO) and 
prostaglandins that further induce cartilage catalysis. 
  
Suppression of remodeling processes:  
Remodeling process is regulated by insulin-like growth 
factor-1 (IGF-1). IL-1 has ability to inhibit transforming growth 
factor-beta which is responsible for chondrocytes 
proliferation. This inhibition of chondrocyte proliferation will 
suppress the production of type II collagen and 
proteoglycans which are building blocks of joint cartilage. IL-
1 is also associated with apoptosis of chondrocytes as well 
as production of nitric oxide (NO) and prostaglandins. 
The complete understanding of these events and the 
underlying molecular mechanisms provides the opportunity 
to explore new potential therapeutic targets that can inhibit 
the degradation events or induce the regeneration events. 
It has been found that OA has genetic determinants in 
some families. The increased incidence of osteoarthritis (OA) 
in some families and identification of mutation in these genes 
encoding structural cartilage matrix proteins are strong 
indication of the genetic component in OA etiology. Specific 
mutations in these genes results in structural changes that 
lower the threshold at which biochemical stresses tend to 
induce OA (Markenson, 2015).  
Chang et al. (2010) studied effect of weight bearing 
habits of OA patients and found that dynamic knee 
alignment during weight bearing phase of walking is a 
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predisposing factor of knee OA. This phenomenon is more 
evident in old age and in obese. 
 
 
 
Fig. 1. This figure provides visual description of 
clinically important components of the joint. 
 
OSTEOARTHRITIS TREATMENT 
The goal of osteoarthritis treatment is to control 
symptoms, prevent disease progression, and improve 
functionality and quality of life. A successful treatment plan 
should include changes in lifestyle as well as non-
pharmacological and pharmacological options. A patient with 
osteoarthritis can live active and productive life despite 
limitations of OA. Only currently available and clinically 
accepted modification of lifestyle, non-pharmacological and 
pharmacological interventions, surgical replacement of joint 
and quality of life enhancing devices are discussed here. 
 
Modification of Lifestyle 
Most of the clinician considers lifestyle changes as the 
first line management option after the diagnosis of OA. This 
can be achieved by modifications in lifestyle such as rest, 
exercise, diet control, learning self-care and having a “good 
attitude”. 
  
Rest  
It is the basic preventive option which can limit the 
degradation of the joint. Progressive degradation of joint can 
be avoided by avoiding prolonged exposure to vocational 
and recreational activities that require repetitive motions, 
bending and heavy weight lifting. However mild recreational 
activities such as walking may not effect joint degradation 
and should not be avoided (Sun et al., 2007). 
 
Exercise and physical therapy:  
Exercise and physical therapy are very useful options for 
improving muscle strength as well as improving joint health 
and functionality. Exercise will help in weight control and 
strengthening joint. Physical therapy is required when a 
patient do not respond to exercise. Deyle et al. (2000) found 
that physical therapy has significantly improved OA 
management outcomes as compared to ultrasound therapy. 
A clinician should devise an exercise or physical therapy 
regimen which is feasible for social and occupational needs 
of the patients. Usually low-impact aerobic exercises are 
recommended such as walking, bicycling and swimming. 
Physical therapy significantly controls OA symptoms and 
improves strength of quadriceps, adductor and abductor 
muscles that further facilitate hip and knee joint functionality. 
 
Diet Control 
 As evident from the studies of Chang et al. (2010), 
obesity is the major predisposing factor of OA in 66% 
patients. The studies of Wang et al found obese patients 
have three to four time greater risk of primary joint 
replacement. David and Yuqing, (1998) concluded in his 
study that reducing as little as 11 pounds weight reduces the 
chances of OA by 50% in women. Thus diet control to 
reduce weight and body mass index (BMI) is the first line 
treatment options for these patients. Taking low fat and 
controlled amount of carbohydrates significantly helps in 
weight loss. Supplementation of the specific digestive 
enzymes in feed improves its nutritional value by increasing 
its digestion efficiency and enzymes help in the breakdown 
of anti-nutritional factors (Imran et al., 2016). Most clinicians 
recommend combination of diet control and exercise as 
means to reduce body weight. 
 
Learning self-care  
Education of self-care principles should be the first step 
after the diagnosis of OA and should be continued even after 
the disease is controlled. A patient should be educated about 
the disease pathology, treatment options and self-care. A 
patient should be properly educated about the exercise or 
diet control plans and should be actively involved while 
planning the treatment regimen. A patient should also learn 
proper resources for self-care information and patient 
oriented support programs available in his community. 
 
Non-Pharmacological Interventions for the 
Management of OA 
The interventions, other than drugs, that are used to 
control the symptoms of osteoarthritis are discussed here; 
 
Joint Surgery  
Joint Surgery is performed when OA medications fail to 
manage symptoms. The effectiveness of joint surgery 
depends upon the assessment of need of surgery and 
evaluation of risks versus benefits ratio. Medicines must be 
given first preference and if joint surgery is requisite, the 
whole plan must be discussed with the patients. There are 
two types of joint surgeries that have gained clinical 
acceptance for Osteoarthritis of weight bearing joints. 
 Total Joint Replacement (Arthroplasty): Total 
joint replacement is required when drugs fail to 
manage pain and it becomes very difficult to perform 
the household tasks (MBHPM, 2013; CCHL, 2015; 
MHS, 2013).  
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 Osteotomy: In osteotomy, a small part of the lower 
joint part is remove which shifts the weight on the 
other parts of the joint and may prevent damaged 
bones from rubbing with each other. This prevents 
deteriorated parts of the joints from further stress 
(WebMD, 2013; Mehta and Parihar, 2012). 
  
Transcutaneous Electrical Nerve Stimulation (TENS) 
TENS is a non-invasive technique which involves 
electrical excitations of nerve in order to reduce pain. Both 
high frequency (>50Hz) and low frequency (<10Hz) electrical 
currents may be used (Robinson and Lynn, 2007). TENS are 
effective in controlling the symptoms of the OA but there is 
also a significant role of “placebo effect”. However, many 
clinicians are using this technique especially in hip 
osteoarthritis. 
 
Rational Field Quantum Magnetic Resonance (RFQMR) 
This technique exposes the affected joint to quantum 
electromagnetic radiation wbhich leads to the activation of 
chondrocyte and the stimulation of regeneration pathways 
(Vasishta et al., 2004). 
  
Thermotherapy and Cryotherapy 
Thermotherapy involves the application of the heat to 
the effected joint. Application of heat with heating pads and 
towels improves circulation and relaxes the muscles 
(Brosseau et al., 2003). Cryotherapy involves the application 
of cold to the effected joint. Application of cold with cold 
compresses and ice bags reduces pain and swelling, 
constricts blood vessels and block nerve impulses to the joint 
(Carol Eustice, 2015).  
 
Mobility Shoes 
It has long been understood that walking with thin and 
flexible shoes mimics the walking barefoot. Najia et al. 
(2013) have designed “mobility shoes” that adapt the 
patients gait after long term use. The sole of these shoes 
have cuts and grooves that shift the body weight from knee 
joint and the gait adaptation persists even after the shoes are 
removed. In a 6 month study, they showed mobility shoes 
can prevent disease progression and may be used to train 
osteoarthritis patients to beneficially adapt their gait 
mechanics. From these results, mobility shoes appear to be 
an ideal supportive device. 
 
Pharmacological Interventions for OA 
Management 
Most clinicians consider pharmacological agents as first 
line treatment option for the relief of pain. Clinically 
acceptable pharmacological interventions range from over 
the counter analgesics to topical preparations to intra-
articular injections to new disease modifying osteoarthritis 
drugs (DMOADs). Today, the pathways leading to joint 
degradation and their molecular mechanism are completely 
understood. This provides the opportunity to selectively 
inhibit destructive pathways or to induce constructive 
pathways (Figure 2).  
Usually analgesic like NSAIDs, selective COX-2 
inhibitors, corticosteroids, narcotics derivatives and some 
topical preparations are prescribed for pain relief. But these 
drugs do not alter the course of joint degeneration. Last 
decade has witnessed the evolution of DMOADs which 
prevent joint degeneration or induces joint regeneration. All 
these pharmacological classes of drugs and their clinical 
effectiveness is reviewed here. 
 
Acetaminophen  
Acetaminophen or paracetamol has proved to be 
effective in the management of mild to moderately OA. 
Acetaminophen relieves OA associated pain but it lacks anti-
inflammatory properties. Acetaminophen is a selective 
cyclooxygenase-2 (COX-2) inhibitor but its anti-inflammatory 
properties are limited due to high concentration of peroxides 
at the inflammation site (Hinz et al., 2008). However, better 
safety profile of acetaminophen compared to NSAIDs makes 
it the drug of choice as first line treatment. Panadol and 
Tylenol are two common brands prescribed by orthopedics 
in recommended dose of 500mg every 4 hours or 1000mg 
every 8 hours, not exceeding 4g a day. Alcohol is 
contraindicated with acetaminophen because it increases 
the risk of hepatic damage, thus an alcoholic should consult 
his pharmacist before he starts acetaminophen (FPC, 2013). 
Madni et al. (2016) documented that immediate release 
tablet released all contents at acidic pH in less than one 
minute. 
 
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 
The patients who do not respond to acetaminophen are 
treated with NSAIDs. They effectively reduce pain and 
inflammation in mild to moderate OA. The clinical efficacy of 
all NSAIDs is almost equal thus a pharmacist should select a 
drug or brand on the basis of safety profile and financial 
status of the patient. 
 
Over The Counter (OTC) NSAIDs: These drugs inhibit both 
isoforms of cyclooxygenase (COX) enzymes, COX-1 and 
COX-2. They provide effective relief from mild to moderate 
OA pain due to inhibition of COX-2 enzymes. Inhibition of 
COX-1 enzyme inhibits production of prostaglandin 
mediators of inflammations (Knights et al., 2010). But 
Inhibition of prostaglandin also exposes gastric mucosa to 
acidic degrading environment. Gastric ulceration and renal 
failure are two serious complications that are associated with 
the prolonged use of the NSAIDs. Almost 30 to 40 percent 
patients tend to discontinue NSAIDs due to these problems. 
These are advised to be taken with food or antacids at the 
lowest effective dose. Ibuprofen (Brufen and Actifen) 400mg 
every 6 or 8 hours and Naproxen (Arthrox and Aproxen) 
500mg every 12 hours are two common OTC drugs used for 
OA pain and swelling. However, some clinician may prefer 
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Diclofenac sodium (Voltaren), Piroxicam (Feldene) and 
Sulindac. 
 
Selective COX-2 Inhibitors: Celecoxib is the only clinically 
accepted drug of this class which selectively inhibits COX-2 
enzymes. Celecoxib lacks gastro-intestinal side effects and 
shows activity comparable to the NSAIDs. However, use of 
Celecoxib has been associated with increased incidence of 
myocardial infarction (Deeks et al., 2002). Celecoxib 
(Osteoxib) is given orally as 200mg every 12 hours or 
100mg every 6 hours. 
 
 
 
 
 
Fig. 2. An elaboration of induction of cartilage degradation pathways (green) and inhibition of regeneration 
pathways (red), and drug targets in these pathways to cure osteoarthritis.  
The boxes shows potential of Interleukin-1 to induce some steps (green box) and to inhibit some steps (red box) as well as 
the inductive effect of these steps on one another (blue arrows). Different therapeutic agents can target Interleukin-1 pathway 
at different steps to inhibit (red arrows) or induce (green) these steps. 
 
Topical Analgesics 
Many pain relieving creams, ointments and sprays are 
available over the counter with proven efficacy in the 
management of Osteoarthritis symptoms. Methyl salicylate 
(Metsal, Iodex, Wintogeno) and topical formulations of other 
NSAIDs are helpful to patients who cannot tolerate these 
drugs systematically (Lin et al., 2004). Capsaicin (Zostrix, 
Finalgon) acts by inhibiting the synthesis of neuropeptide 
“substance P”. It also increases blood circulation and 
produces heat. Topical Capsaicin has also been prescribed 
in combinaton with other analgesics (Altman et al., 1994). 
Methanol has been used as an ingredient of topical 
preparation. Methanol produces feeling of cold by the 
activation of cold-sensitive TRPM8 receptors and produces 
analgesia due to activation of k-opioid receptors (Eccles, 
1994). Lidocaine 5% patches are available for OA 
management. One comparative clinical trial has proved that 
lidocaine patches are as effective as selective COX-2 
inhibitors (Kivitz et al., 2008). 
 
Narcotic Derivatives 
The long term use of narcotics is allowed only in cancer 
and its chronic use in other diseases, including OA, is 
controversial amid risk of addiction, dependence and 
hyperalgesia. Narcotics act by selectively binding 
endogenous opioid receptors. They are prescribed in OA in 
lowest effective dose for shortest possible time. Many 
clinicians use narcotics in combination with non-
pharmacological therapies. Narcotics provide effective 
analgesia and moderately improved joint functioning. 
Codeine and oxycodone are discouraged as first line 
treatment for OA pain (Goodwin et al., 2009). In another, 
Langford et al. (2006) showed that fentanyl patch improve 
pain and functionality in hip and knee OA. Fentanyl 
administration through patches is more tolerable and 
provides continuous medication for hours. Fentanyl 
transdermal (such as patches) is especially considered for 
patients who develop tolerance to other opioids. Extended 
release formulations of oxycomorphone have been rated 
from excellent to good by 80% clinical practitioners for 
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effective analgesia and improve functioning of joints 
(Gibofsky and Barkin, 2008).  
Tramadol is codeine like molecule but it is not 
considered narcotic. Tramadol acts on central mu-receptors 
and inhibits the reuptake of norepinephrine and serotonin. Its 
analgesic effects are better than NSAIDs but it lacks anti-
inflammatory effects. Its clinical acceptance is limited due to 
tolerance and withdrawal effects. Tramadol (Merlon, Opadol 
SR) is given 50mg every 6 hours.  
 
Corticosteroids  
Corticosteroids also known as glucocorticoids are powerful 
anti-inflammatory hormones that are prescribed for acute 
pain and inflammation that is not responsive to NSAIDs. 
Prednisolone (Deltacortril), betamethasone (Betnovate, 
Betnesol), triamcinolone (Kenacort) and misoprostol 
(Cytotec) are the corticosteroids commonly prescribed by the 
physicians for knee OA (Schumacher, and Chen, 2005). 
Misoprostol (200mcg) is also available in combination with 
diclofenac sodium (50mcg and 75mcg) as Arthrotec tablet. 
Corticosteroids inhibit the production of inflammatory 
mediators including interleukins, interferons and TNF alpha 
etc. In OA, corticosteroids are applied topically or 
administered intra-articularly i.e. directly into joints and their 
effect lasts for 4 to 6 weeks. Dose of the injection depends 
upon the size of the joint and it should be administered by a 
trained health professional to avoid complications like 
infection or joint injury (Bellamy et al., 2006). 
 
Disease Modifying Osteoarthritis Drugs 
Abbreviated as DMOADs, these drugs are capable of 
stimulating regeneration of articular cartilage. DMOADs have 
made big impact on osteoarthritis treatment during last 
decade. Currently, a large number of drugs from different 
pharmacological classes that inhibit one or more OA 
pathophysiological pathways are under research, however, 
only Diacerein and hyaluronic acid are available in market for 
oral administration. This review will highlight the DMAODs 
that have shown promising efficacy in research and clinical 
trials. 
 
Matrix metalloproteinase (MMP) Inhibitors 
MMPs are the major component of cartilage damage. 
Today, activation of MMPs and their mechanism of cartilage 
degradation are understood. Thus, inhibition of MMPs 
provides an interesting target for disease modifying 
treatment. Broad spectrum MMP inhibitory drugs like BAY 
12-9566 (Leff et al., 2003) and PG-116800 (Krzeski et al., 
2007) have demonstrated improved cartilage regeneration in 
clinical trials. However, emergence of mild to moderate 
musculoskeletal problems including pain and swelling has 
restricted further research. Recently, MMP-13 and ADAMTS-
5 have been recognized as chief metalloprotease enzymes 
of cartilage and targeting these catalytic enzymes will 
provide safe disease modifying treatment (Stanton et al., 
2005). Recently, Baragi et al. (2009) have proposed a new 
class of MMPs inhibitors non-hydroxamic acid containing 
compounds that have high degree potency against MP-13 
and show improved safety and pharmacokinetic profile. 
Researches have also evaluated Doxycycline as DMOAD 
due to its ability to inhibit MMPs. Early clinical trials showed 
promising data but a recent study has concluded that 
Docxycycline has very little to no benefit in osteoarthritis (da 
Costa et al., 2012). 
  
Biophosphonates 
Biophosphonates are antiresorptive agents that have 
proved to be effective in preventing the degradation of the 
bony components of the joints. Two clinical trials on a 
biophosphonate drug risedronate by Spector et al. (2005) 
and Bingham et al. (2006) have shown that the prevention of 
radiographic degradation of OA has been insignificant. Most 
recently, results of clinical trials of two biophosphonate drugs 
tiludronate (Moreau et al., 2011) and zoledronic acid (Laslett 
et al., 2012) showed promising results in reducing 
osteoarthritis pain and disease progression. 
 
Cytokines Inhibitors 
Cytokines, especially interleukin-1 (IL-1), are involved in 
the degradation of cartilage through induction of MMPs and 
suppression of remodeling process. Cytokines are released 
by cartilage as well as synovium and bone (Pelletier et al., 
2001). Thus cytokines and cytokine receptors have emerged 
as interesting research topic for drug developing 
researchers. In rheumatoid arthritis, Interleukin-1 receptor 
antagonist (IL-1RA) (Caron et al., 1996) and transfection of 
IL-1RA genes into knee joints (Fernandes et al., 2000) have 
proved their efficacy but they are not yet tested in OA. 
Inhibition of Interleukin-1 converting enzyme has also been 
shown to be effective for the prevention of articular cartilage 
degradation (Saha et al., 1999). Cytokines inhibitors have 
shown to reduce the degradation of the human cartilage in 
in-vitro experiments (Kobayashi et al., 2005). Only a few 
drugs of this class have been tested in clinical trials for 
osteoarthritis treatment with no evidence of significance 
effectiveness. In 2005, a clinical trial was conducted with 
cytokines inhibitor drug Anakinra injected intra-articularly as 
a single dose. Anakinra did not show significant beneficial 
effects on the management of symptoms and prevention of 
disease progression (Chevalier et al., 2005). 
 
Calcitonin 
Calcitonin is a thyroid hormone which has been used for 
the treatment of osteoarthritis for more than three decades. 
Oral Salmon Calcitonin has been safe, and effective for 
increasing bone mineral density and reduction in bone 
resorption. Recently, the study of Manicourt et al. (2006) 
showed that 1mg of Salmon Calcitonin improved physical 
functions after 42 days of treatment and reduced levels of 
circulating MMP-13 after 84 days of treatment. On March 5, 
2013, U.S. Food and Drug Administration (FDA) have 
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approved Salmon Calcitonin for postmenopausal OA (FDA, 
2013. 
 
Inducible Nitric Oxide Synthase (iNOS) Inhibitors 
Nitric oxide plays a major role in the pathogenesis of OA 
in three ways. First, it can induce and promote the 
production of MMP enzymes. Second, it can cause 
apoptosis of chondrocytes. Third, it promotes inflammatory 
component of OA thus worsening the symptoms. This 
production of nitric oxide is induced by nitric oxide synthase. 
Naproxcinod, a derivative of naproxen, is first compound of 
this class undergoing clinical trials for safety and efficacy 
(Geusens, 2009). Pfizer Inc. has now conducted clinical trials 
on a drug SD-6010 which has been shown to be safe 
tolerable and effective in obese and overweight OA patients 
(Pfizer Incorporation, 2016). 
 
Diacerein 
Diacerein, a semisynthetic anthraquinone, is a 
symptomatic disease modifying OA drug. Diacerein directly 
inhibits interleukin-1 (IL-1) and stops the cascade of 
pathways modulated by IL-1. It suppresses the IL-1 induced 
production of MMPs and pro-inflammatory agents. Diacerein 
promotes the expression of TGF beta-1 and TGF beta-2 thus 
promoting the synthesis of articular chondrocytes (Mahajan 
et al., 2006). Thus, diacerein appears to be an ideal DMOAD 
which can control OA symptoms, prevents degradation of 
joint and promotes the synthesis of new cartilage. Its daily 
dose is 80mg to 100mg in two divided doses. It provides 
symptomatic control after 4 weeks of administration and 
remains for up to 12 weeks after discontinuation. Its oral 
bioavailability is 35-55%. During absorption, diacerein is 
converted to its active metabolite Rhein (Tamura et al., 
2001). Diacerein is the only DMOAD available in market for 
OA. In India and Pakistan, Diacerein tablets (50mg) are 
available with brand name Dicerin, Diora, Diritis, Karty and 
Rein. The clinical acceptability of oral diacerein has been 
marred by the gastrointestinal adverse effects like increased 
gastric motility and diarrhea (Louthrenoo et al., 2007). This 
requires the need of a “para enteral” and joint specific 
formulation which can avoid gastrointestinal exposure and 
subsequent first pass effect. Jain et al. have reported solid 
lipid nanoparticles of diacerein to target drugs joint bypassing 
GIT (Jain et al., 2013). Recently, we took research in this 
field one step ahead by preparing solid lipid nanoparticles 
that can sustain drug release action for as long as three 
days. In addition, we were able to get thermoresponsive drug 
release which shows promise to enhance drug release at 
inflamed joints (Rehman et al., 2015). Another strategy 
which we have used to enhance bioavailability of diacerein 
and to bypass GIT is by encapsulating it inside vesicles of 
non-ionic surfactants, also termed as niosomes. These 
vesicles showed the potential to sustain drug release rate for 
more than 12 hours and improve solubility of drug as well as 
bioavailability in rats (Khan et al., 2015a; Khan et al., 2015b). 
Madni et al. (2017) demonstrated that dialysis tube cab 
affect drug release behavior independent of drug delivery 
system. 
 
Hyaluronic Acid 
Hyaluronic acid is a mucopolysaccharide which 
maintains lubrication of synovial fluid. It is administered 
intraarticularly into affected joint. Hyaluronic acid and its 
several derivatives are commercially available. Bellamy et al. 
(2006) conducted a comparative study of various hyaluronic 
acids derivatives and found that all are effective in reducing 
OA pain and functioning to some extent. Their action 
remains for 5 to 12 weeks after injections. Euflexxa, Hyalgan, 
Orthovisc, Supartz and Synvisc are most accepted brands of 
hyaluronic acid and its derivatives. Intraarticular 
administration should be conduct by an expert physician or 
technician because an improper injection may damage joint 
and its components (WebMD, 2017). 
 
Dietary Supplements  
Supplements constitute an important part in OA 
treatment regimen. Supplements are used in combination 
with OA drugs and usually lack any side effects. These 
supplements are not controlled by regulatory authorities and 
have very little clinical data to prove their effectiveness. It is 
usually thought that a costly supplement is better than a 
cheaper one but this is not the case. Concomitant use of 
supplements with OA drugs may lead to serious interaction 
or overdosing, thus, a patient should consult his physician or 
the pharmacist before spending large amount of money on 
these supplements. 
 
Glucosamine Sulphate 
The most common OA supplement, glucosamine 
sulpahte, is a carbohydrate with an amino and a sulphur 
group. It is building block of cartilage. After oral 
administration, it is taken up selectively by cartilage and it 
may be used as building block of chondroitin Sulphate. Perry 
at al. (1972) demonstrated that Glucosamine Sulphate 
primarily protects joints from degradation and promotes 
cartilage regeneration. Its analgesic and anti-inflammatory 
effect has slow onset but later equal to most of the NSAIDs. 
Vaz (1982) studied that action of glucosamine after two 
weeks was lower than that of Ibuprofen but glucosamine 
showed better results after four weeks and so on. Its daily 
recommended dose 1000mg in single or two divided doses 
and it may be taken with milk or soft drinks. 
  
Chondroitin Sulfate 
It is a glycosaminoglycan which provides elasticity and 
resistance to cartilage. The results of clinical trials have 
shown that chondroitin sulfate is an effective supplement for 
management of osteoarthritis pain and slows the 
degeneration of joints (Uebelhart et al., 1998). However it is 
not superior to chondroitin sulfate. Its daily oral dose is 
1000mg once daily or in two divided doses (Leffler et al., 
1999). 
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Glucosamine and Chondroitin Sulfate are most 
commonly used and are also available in combination which, 
hypothetically, provides a better management of moderate to 
severe arthritis. Forever Freedom® is a glucosamine sulfate 
and Chondroitin Sulfate supplement which also contains 
very low levels of Methylsulfonylmethane and Aloe Vera 
(Forever living products, 2015). 
 
SAMe 
SAMe (s-adenosylmethionine) is a compound which is 
synthesized in our body. It exerts its action by inducing the 
synthesis of hormones, neurotransmitters and phospholipids. 
Studies have demonstrated that SAMe promotes production 
of cartilage from chondrocytes and also shows analgesic 
effects. It is better tolerated than NSAIDs and 
contraindicated in patients with depressive disorders. 
However, its use is limited due to high cost and relatively 
slower onset of action, almost thirty days (Hardy et al., 
2002). It is not currently available in India or Pakistan. 
 
MSM 
Methylsulfonylmethane (MSM) is found in green 
vegetables, fruits and also in human adrenal gland. Short 
term clinical trials have showed that MSM is modestly anti-
inflammatory and analgesic. MSM is a second line OA 
supplement and usually available in combination with other 
supplements such as glucosamine sulfate (Kim et al., 2006). 
 
Turmeric and Ginger 
Turmeric (Curcuma longa) and Ginger (Zingiber 
officinale) belong to family Zingiberaceae and have been 
found to be a second line supplement for OA. Turmeric has 
anti-inflammatory effect due to active ingredient curcumin 
which inhibits cyclooxegenase-2, prostaglandins and 
leukotrienes. Ginger exerts its effects due to inhibition of 
cyclooxygenases (subtypes 1 and 2) and lipoxygenases. 
Ginger may also inhibit TNF-alpha and prostaglandins. 
Clinical trials have shown that ginger has modest 
improvement in OA pain during walking phase (Altman and 
Marcussen, 2001). There are no clinical trials for turmeric 
however results of some preliminary research showed that it 
relieves the symptoms of OA (Deodhar et al., 1980). 
 
Devil’s Claw and Cat’s Claw 
Devil’s Claw (Harpagophytum procumbens) and Cat’s 
Claw (a common term for many plants especially Uncaria 
guianensis and Uncaria tomentosa) are native to Africa and 
get the name “claw” due to the shape of their fruits. Devil’s 
claw activity is attributed to glycoside harpagoside. 
Harpagoside inhibits cyclooxygenase-2 and it is well 
tolerated. Usually Devil’s Claw supplements are 
recommended in combination with NSAIDs (Wegener and 
Lüpke, 2003). Cat’s Claw inhibit TNF-alpha and, to a lesser 
extent, prostaglandins (Piscoya et al., 2001). Devil’s Claw is 
most commonly used second line supplement for the 
management of OA. It inhibits the hepatic metabolism of 
many drugs including warfarin and NSAIDs. Thus patient 
taking warfarin or NSAIDs should consult their physician and 
the pharmacist before starting the supplement. 
 
Vitamins 
Patients with Vitamin D deficiency are at three time 
higher risk of getting OA. The study of Jon Giles (2009) 
showed that Vitamin D and exposure to sunlight reduce the 
degeneration and loss of cartilage in OA patients. Vitamin B6 
has demonstrated reduced inflammatory response in arthritis 
(Huang et al., 2010) while Vitamin B12 and folic acid 
(Vitamin B9) have shown significant management of OA of 
hands (Flynn et al., 1994). 
 
DESIGNING AN OSTEOARTHRITIS 
TREATMENT REGIMEN 
OA is generally a disease of elderly who have complex 
comorbidities. According to U.S. National Institute of Health 
guidelines on OA treatment, to facilitate the routine working 
of patients, it is devisable to optimize every aspect of 
patient’s treatment plan (NIAMS, 2016). Ideally, the 
treatment plan should be designed on the basis of severity of 
disease as shown in the Table 1. 
 
THE CONCEPT OF MULTIDISCIPLINARY 
HEALTH CARE TEAM 
It is clear that any clinical stage of OA has complex 
treatment regimens and involves different services of 
physicians, pharmacist and nurses. Thus an effective patient 
care plan must involve the synergistic efforts of these entire 
health professional in accordance with the patient’s needs. 
Physician is responsible for diagnosis of the patient, 
prescribing the drug and counsel about the precautions and 
lifestyle modifications. Nursing care is confined to 
hospitalized patients and involves assessment of symptoms, 
psychological status, treatment related problems and the 
administration of medicines. Pharmaceutical care of a patient 
includes preventing drug related problems, counseling and 
educating patients about the treatment and ancillary devices, 
helping physicians in developing patient oriented treatment 
plan. In the same way, a patient should also take 
responsibility of his health by knowing about OA, its risk 
factors, treatment options, precaution and changes he 
should adapt. Recently, Grotle et al. (2010) evaluated the 
current trends of health care teams and proposed that 
physicians and nurses alone cannot manage the treatment 
of complex chronic diseases like osteoarthritis. The concept 
of multidisciplinary health care team incorporates a broader 
range of health professional under same umbrella. 
According this concept, the complete diagnosis, treatment, 
prevention of further treatment and the reduction of socio-
economic limitations requires a multidisciplinary health care 
team as shown in Table 2. 
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Table 1. Recommendations for designing treatment plan on the basis of osteoarthritis severity  
Severity of  
osteoarthritis 
Recommended Treatment Regimen* 
Non-pharmacological Approach Pharmacological Approach 
Mild cases or as 
prevention after the 
treatment 
Modification of life style including diet 
control and exercise, and supplements 
Analgesic should be used on when needed basis 
Mild to moderate Modification of lifestyle including 
reductions in weight and rest 
Drugs like analgesics or a DMOADs 
Moderate to severe Modification of lifestyle including 
reduction in weight, exercise, 
adaptation of gait and rest, and novel 
non-pharmacological OA treatment 
Drugs like like analgesic, intra-articularly injected drugs 
and DMOADs 
Severe cases Modification of lifestyle including rest 
and modification of gait, novel non-
pharmacological interventions and/or 
surgical procedures 
Drugs like analgesics and DMOADs. If patients does 
not respond to medication, joint surgery is performed 
*These recommendations only outline the components of the treatment plan. Choice of drugs may vary depending upon 
local laws, availability of interventions or the personal experience.  
 
Table 2. Structure of multidisciplinary health care team (MHCT) for osteoarthritis patients 
Health Care Professional Responsibilities 
General (Primary care) 
Physician 
GP is the person who diagnoses OA and help you in establishing the whole team. 
Rheumatologist  
 
The doctor specialized in arthritis and related diseases will perform further diagnosis and 
design the treatment plan.  
Orthopedic Surgeon Orthopedist is specialized in surgery of joints and bones, and should be included in the 
teams for moderate to severe OA patients.  
Pharmacist Pharmacist may guide patient as well as other members of the team about medicine, its 
administration, economic aspects and side effects. In some setups, the follow up visits 
and monitoring of ambulatory patients is also carried by the pharmacist. 
Physical, acupuncture and 
occupational Therapist 
 
May guide the patient on how to protect joint, how to conserve energy and how to perform 
routine activities without pain. These services must be conducted by registered 
practitioners.  
Nurse  Nurse may care hospitalized patients and may educate the patients on how to walk or 
sleep, how to take medicines. Nurse may also specialize in rheumatology. 
Social workers  Social workers may help patients by assisting them in avoiding social limitations, home 
care and unemployment problems.  
Others In certain cases, a psychiatric or geriatric may also be hired to assist in physical and 
mental activity of the patient. 
The concept of teamlet Teamlet means a little team. According to this concept, a health coach first meets the 
patient and inquires about his needs. In a MHCT, a health coach design the necessary 
members of teams and guides the team to design his treatment plan.  
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The study of Brenda Goodman also suggested the need 
of multidisciplinary approach for OA treatment and stressed 
that the structure of Multidisciplinary Health Care Team 
should be based on individualized patient needs (Goodman, 
2015). This may also be affected by local job structures of 
different health professional as well as regulatory affairs. 
However, establishment of an effective treatment plan, it’s 
monitoring and achievement of better treatment outcomes is 
possible only by close collaborative work of these 
professionals, preferably in multidisciplinary health care 
teams. 
 
CONCLUSION  
Osteoarthritis is a chronic disease that reduces 
functionality of affected joint and restricts patient’s daily life. 
Treatment of OA should be based on evidence based 
approach keeping in mind the patient needs. Modification of 
life style significantly improves routine function and should be 
given first consideration. As evident from above discussion, 
several non-pharmacological and pharmacological 
interventions are available that can control the pain and 
swelling of joints. The choice of intervention also depends 
upon many factors like age, gender, profession, weight, joint 
type and severity of damage. The evolution of DMOADs has 
made promises of preventing joints from injury and 
recovering degraded cartilage. However, association of mild 
to severe side effects with these agents has called for the 
joint specific formulations. Effective osteoarthritis treatment 
should embrace the concept of “health care team” in which 
physician, specialists, pharmacist and nurse work together to 
define effectively the complete treatment plan including 
modification of life style, non-pharmacological supportive 
interventions and pharmacological therapeutic agent. 
 
Novelty Statement 
This comprehensive review article is first of its kind (to 
our knowledge) in that; 
1. It covers all conventional and modern, 
pharmacological and non-pharmacological 
treatment options. Attempt has been made to cover 
all new therapeutic agents in market and those in 
various phases of clinical trials.   
2. Pathogenesis of osteoarthritis and the opportunity of 
new therapeutic targets has been elaborated with 
easy to understand flow diagram (Figure 2).  
3. The concept of clinical stage of disease based 
treatment plan and multidisciplinary health care 
team has been highlights.  
This review articles has been compiled with special 
emphasis on clinical data and will be very helpful to readers 
who are active practitioners or want to conduct research on 
any aspect of osteoarthritis. 
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